Cases & investigations

Cases & investigations

Corvus Pharmaceuticals

Kaskela Law LLC is investigating Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) (“Corvus”) on behalf of the company’s stockholders.

Since June 2023, shares of Corvus’ common stock have declined from a trading price of above $3.50 per share to a current trading price of approximately $2.30 per share, a cumulative decline of over 34% in value.

The investigation seeks to determine whether Corvus and/or the company’s officers and directors violated the securities laws or breached their fiduciary duties to the company’s investors in connection with recent corporate actions.

Corvus shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (484) 229 – 0750 or (888) 715 – 1740, or by completing the form on this page, for additional information about this investigation and their legal rights and options.

Submit Your Information

  • This field is for validation purposes and should be left unchanged.

Contact Us

  • This field is for validation purposes and should be left unchanged.